LIVE! Testing Board®: Breaking Down Pathologic Reports to Identify Actionable Markers in Patients with NSCLC

Overview:

Given the availability of highly efficacious treatments for NSCLC, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. In addition to detecting common mutations in lung cancer genes, such as EGFR, ALK, and KRAS, developments in molecular testing via tissue or liquid biopsy enable less frequent targetable mutations in NSCLC, including alterations and mutations in MET, ROS1, RET, HER2, and NTRK, to be revealed. Identification of these patients for approved targeted agents or clinical trial participation, however, requires rapid and reliable testing using the most appropriate assay.

This LIVE! Testing Board webcast will provide an in-depth review of current pathologic testing methodology aimed to improve the interpretation of NSCLC testing report results. This program will feature a case-based panel discussion of pathologic reports that identify potential actionable alterations matched to appropriate treatment selection for patients with NSCLC.

Learning objectives:

• Outline recent approaches for biomarker and mutational tests, including NGS and liquid biopsy tests, in patients with NSCLC

• Describe clinical trial evidence concerning the role of biomarker-directed therapies for patients with NSCLC in the context of clinical guidelines for management of advanced NSCLC

• Detail emerging biomarker-directed therapeutic targets and assessment strategies in advanced NSCLC

• Determine the importance of multidisciplinary management for the assessment and interpretation of molecular data in advanced NSCLC

Target Audience:

This educational program is directed toward the CAP audience, primarily pathologists and other healthcare professionals, involved in the diagnosis and treatment of NSCLC.

Coming Soon!